Cumulatively, these results suggest that targeting pathways involving Oct1 in CD4+ T cells may provide a novel therapeutic avenue for the treatment of MS and other neuroinflammatory diseases, while largely sparing beneficial immune function. This evidence concerns the gene POU2F1 and myeloid sarcoma.